Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Burt Nabors

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Neuro-Oncology|September 19, 2025
"Successful use of response leads to ONC201 approval"Louis Burt Nabors
Journal of the National Comprehensive Cancer Network : JNCCN|May 27, 2016
Central Nervous System: Notable Developments in the Management of Primary and Recurrent GliomasLouis Burt Nabors
Biomolecules|March 25, 2015
Growth factor dependent regulation of centrosome function and genomic instability by HuRNatalia Filippova, Xiuhua Yang, Louis Burt Nabors
Neuro-Oncology|December 18, 2024
NCCN CNS Tumor Guidelines Update for 2024Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, et al.
Future Oncology (London, England)|March 23, 2011
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesDavid A Reardon, Bart Neyns, Michael Weller, et al.
Cancer|May 29, 2023
Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort studyDagoberto Estevez-Ordonez, Moaaz Abdelrashid, Elizabeth Coffee, et al.
Journal of Neuro-Oncology|January 15, 2018
Handedness and the risk of gliomaBriana Miller, Noah C Peeri, Louis Burt Nabors, et al.
CNS Oncology|July 18, 2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastomaGarni Barkhoudarian, Michael Badruddoja, Nicholas Blondin, et al.
Oncotarget|February 27, 2016
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcomeMichael Weller, Louis Burt Nabors, Thierry Gorlia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementStephen J Bagley, Shawn Kothari, Rifaquat Rahman, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Neuro-Oncology|September 19, 2025
"Successful use of response leads to ONC201 approval"Louis Burt Nabors
Journal of the National Comprehensive Cancer Network : JNCCN|May 27, 2016
Central Nervous System: Notable Developments in the Management of Primary and Recurrent GliomasLouis Burt Nabors
Biomolecules|March 25, 2015
Growth factor dependent regulation of centrosome function and genomic instability by HuRNatalia Filippova, Xiuhua Yang, Louis Burt Nabors
Neuro-Oncology|December 18, 2024
NCCN CNS Tumor Guidelines Update for 2024Louis Burt Nabors, Jona Hattangadi-Gluth, Craig Horbinski, et al.
Future Oncology (London, England)|March 23, 2011
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesDavid A Reardon, Bart Neyns, Michael Weller, et al.
Cancer|May 29, 2023
Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort studyDagoberto Estevez-Ordonez, Moaaz Abdelrashid, Elizabeth Coffee, et al.
Journal of Neuro-Oncology|January 15, 2018
Handedness and the risk of gliomaBriana Miller, Noah C Peeri, Louis Burt Nabors, et al.
CNS Oncology|July 18, 2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastomaGarni Barkhoudarian, Michael Badruddoja, Nicholas Blondin, et al.
Oncotarget|February 27, 2016
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcomeMichael Weller, Louis Burt Nabors, Thierry Gorlia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2021
Glioblastoma Clinical Trials: Current Landscape and Opportunities for ImprovementStephen J Bagley, Shawn Kothari, Rifaquat Rahman, et al.
Pageof 2